About HepaRegeniX GmbHHepaRegeniX, founded in 2015, specializes in the discovery and development of small molecule kinase inhibitors. The management team, led by Dr. Wolfgang Albrecht, and scientific advisors have over 20 years of experience in the pharmaceutical industry with a proven track record in drug development and cover all disciplines along the value creation chain from early stage discovery through clinical proof-of-concept studies. The unique therapeutic concept for the treatment of liver diseases was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany. Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo A/S, coparion, High-Tech Gruenderfonds and Ascenion GmbH. Ascenion supported the acquisition of the exclusive IP rights.
CEO: Wolfgang Albrecht
5 articles with HepaRegeniX GmbH
10/23/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
HepaRegeniX GmbH Secures Series B Financing in Excess of €11 Mio. to Advance First Drug Candidate to the Clinic
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models
10/25/2019Pharma and life sciences companies strengthen their executive and leadership teams with this week's appointments.
HepaRegeniX GmbH, a preclinical stage company developing a novel therapy for the treatment of acute and chronic liver diseases announced the appointment of seasoned biotech expert Dr. Michael Lutz as new CEO and Managing Director of the company..
HepaRegeniX GmbH Raises €9 Million In A Series A Financing To Develop Kinase Inhibitors For The Treatment Of Acute And Chronic Liver Diseases